Name tweak could boost GLP-1 access for one in eight women suffering PMOS The hormonal condition formerly known as Polycystic Ovarian Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its metabolic and hormonal basis, potentially improving diagnosis and care. This change, coupled with research showing GLP-1 weight loss medications can stabilize insulin levels and reduce testosterone in patients, may increase access to these drugs for women with PMOS, particularly for co-occurring conditions. While direct FDA approval for PMOS is unlikely soon, insurance coverage may be possible for related conditions like Type 2 diabetes, fatty liver disease, or sleep apnea, which are common in women with PMOS.

• The condition previously known as Polycystic Ovarian Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following an international effort to improve clinical care.
• PMOS affects 1 in 8 women globally and is the leading cause of infertility in the U.S., characterized by symptoms like weight management difficulties, mental health struggles, and reproductive issues.
• GLP-1 weight loss medications show promise in stabilizing insulin levels and balancing sex hormones in patients with PMOS, potentially reducing testosterone production.
• While GLP-1s are not yet directly approved for PMOS, women may gain insurance coverage for them if they have co-occurring FDA-approved conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, or obstructive sleep apnea.
• The name change aims to shift focus from ovarian cysts to the underlying metabolic dysfunction, and research suggests significant weight loss with GLP-1s leads to lower testosterone levels and improved period regularity.
• Developing a singular treatment for PMOS is challenging due to symptom variability and difficulties in designing clinical trials, particularly concerning pregnancy risks.
• Patients with PMOS are advised to seek comprehensive metabolic screenings to identify co-occurring conditions that could enable insurance coverage for GLP-1 medications.